Figure 2.

Immunoreactivity of pept^GLZIKALIVax. The O.D₄₅₀ or signal intensity of samples in dose-response curves of peptGL^ZIKALIVax and mutant peptide peptGL^ZIKALIVax-(I8, T12, H14) in relation to anti-ZIKALIVax immune serum (ZIKALIVax serum) at dilution 1:200 measured through peptide-based ELISA. Serum of mice that received heat-inactivated ZIKALIVax at dilution 1:200 served as a control serum. Peptcontrol peptide was used as a negative peptide control. In (A), plates were coated with increasing concentrations of peptides and incubated with a pooled ZIKALIVax immune serum. In (B), peptides at concentration of 3 µg mL⁻¹ were incubated with 14 individual anti-ZIKALIVax immune sera.